On Wednesday, UNAIDS published "Financial Resources Required to Achieve Universal Access to HIV Prevention, Treatment, Care and Support" to present the world with a bottom line: $50 billion a year.
CGD Policy Blogs
"Disappointing" is the only word to describe the news that sponsors of the STEP study, testing Merck's AIDS vaccine candidate, have discontinued the Phase IIb trial. Interim analyses showed that the product doesn't prevent infection or reduce the presence of HIV in the blood once someone is infected, calling a halt to tests of the most promising candidate in the field.
A compelling article in today's New York Times highlights the suffering of individuals in poor African countries who have cancer and other diseases that cause devastating pain. Unlike those of us in rich nations, people facing even the most severe pain in much of the developing world do not obtain common, effective and relatively low-cost pain medication.